The era of generic weight loss drugs is approaching, and the first batch of patents for GLP drugs have expired, leading to a fierce competition among competitors
影殇·天问
发表于 2024-4-8 18:14:16
3777
0
0
The global weight loss drug market is currently divided into two parts. Novo Nordisk's Wegovy and Ozempic, as well as Eli Lilly's Zepbound and Mounjaro, are the most sought after and effective drugs in the market.
However, both companies are unable to provide drugs to more consumers due to production capacity issues. But this has also made the market for generic weight-loss drugs hot. The industry predicts that by 2030, the market size of GLP generic drugs will reach 100 billion US dollars.
The global patent for Saxenda, the injection of Liraglutide, the main component of Novo Nordisk's previous generation product, will expire in some countries this year. It is also one of the first GLP-1 drugs to lose patent protection. Last February, it had already lost patent protection in the Chinese market.
Compared to Wegovy and Ozempic, Saxenda is now somewhat like "tears of the times" (referring to outdated things), but its efficacy is not enough to make up for in quantity. The influx of generic drug companies will create a strong supply of generic drugs and lower prices, thereby expanding the market.
Among them, Biocon, a leading generic drug company in India, has obtained a license to replicate Saxenda in the UK. The CEO of the company, Siddharth Mittal, confidently stated that his team is ensuring Biocon's leading position in the generic pharmaceutical market. The company has also submitted applications to regulatory agencies in the United States and Europe to replicate the drug Liraglutide.
The future is bright
Weight loss pills have already created record breaking profits for Novo Nordisk and Lilly, which has caught the attention of other pharmaceutical companies, and generic drugs are the key way for them to openly compete for market share.
Biocon is a typical example of this. The company stated that it is building infrastructure to seize strategic opportunities centered around GLP drugs. Liraglutide products are just the beginning, waiting for the expiration of patents for more effective Smegglutide and Tezepamide products. The generic drug market is bound to ignite a greater wave of competition.
Mittal stated that weight loss drugs will be a very attractive market for the next 20 years, and the UK's approval of Biocon's production of generic Liraglutide demonstrates Biocon's ability to seize this opportunity.
There are also leaders in the Chinese market. Last year, the Liraglutide biosimilar developed by East China Pharmaceutical was approved for the treatment of obesity. Hangzhou Jiuyuan Genetic Engineering Co., Ltd. announced last week that it is applying to sell Megglutide generic drugs in China to control the blood sugar of patients with type 2 diabetes.
Jiuyuan Genetic Engineering also pointed out that it cannot commercialize drugs before the patent expires unless a court with jurisdiction determines that the patent is invalid. According to Novo Nordisk's annual report, the patent for its semaglutide drug in China will expire in 2026, while the patent for the European and American markets will expire from 2031 to 2032.
Jiuyuan Gene Factory also emphasized that the Chinese market potential of Smegglutide is enormous, with its scale increasing from 2.5 billion RMB in 2022 to 43.9 billion RMB in 2032, with a compound annual growth rate of up to 33%.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Tesla: Model 3 High Performance Edition is expected to start its first delivery in mid June
- Tesla: The Model 3 high-performance version is expected to start its first delivery in mid June, starting today
- Up 77%! Tesla sold over 55000 vehicles domestically in May! Model 3 High Performance Edition is about to begin its first batch of deliveries
- The first batch of L3 level intelligent connected vehicle pilot list has been announced! Nine companies including BYD and NIO have been selected, but Huawei and Xiaopeng are nowhere to be seen
- The Federal Reserve's "Eagle Mouth" still exists! Speech by the first batch of officials after the resolution: Whether interest rates can be reduced depends on a few more data points
- Eisai/Bojian Alzheimer's disease drug rejected by the European Union, and Eli Lilly monoclonal antibody may be affected
- Digital Intelligence Morning Attendance | Nvidia released the humanoid robot training platform, and ByteDance became the first batch of enterprises to join
- AstraZeneca's market value has surpassed £ 200 billion for the first time! The bold bet on anti-cancer drugs is yielding results
- The US government announces the results of the first batch of "drug procurement" negotiations. Gaza ceasefire talks are highly divided. Global market
- Bristol Myers Squibb's original tumor treatment drug Abraxane has been officially launched in China
-
9月5日、蔚来は2024年第2四半期の財政報告を発表し、第2四半期の売上高は174億5000万元で、前年同期比98.9%増加した。今年第2四半期、蔚来は累計5万7400台の新車を納入した。 財報の発表当日、資本市場で前向きなフ ...
- 就放荡不羁就h
- 昨天 12:39
- 支持
- 反对
- 回复
- 收藏
-
小鵬自動車の新車種MONA M 03は肇慶基地で順調に量産され、工事中の瑞慶時代二工場は年内に操業を開始する予定で、広州データ取引所(肇慶)サービス基地は看板を掲げて運営している……実体経済であれ、デジタル経 ...
- slim
- 前天 11:16
- 支持
- 反对
- 回复
- 收藏
-
JPモルガン・チェース首席米経済学者マイケル・フェローリ(Michael Feroli)氏は最近、FRBは9月の会議で金利を50ベーシスポイント引き下げなければならないと述べた。 現地時間の木曜日(9月5日)、フェリリ氏はメ ...
- 不正经的工程师
- 昨天 21:44
- 支持
- 反对
- 回复
- 收藏
-
【クアルコムCEO:サムスンとグーグルと協力してハイブリッド現実眼鏡を開発中】クアルコムのクリスティア・アモン最高経営責任者は、クアルコムがサムスンとグーグルと協力してスマートフォンにつながるハイブリッ ...
- 寒郁轩良
- 昨天 10:33
- 支持
- 反对
- 回复
- 收藏